Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 57.76 USD 0.31%
Market Cap: 117.1B USD
Have any thoughts about
Bristol-Myers Squibb Co?
Write Note

Bristol-Myers Squibb Co
Other Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bristol-Myers Squibb Co
Other Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Assets CAGR 3Y CAGR 5Y CAGR 10Y
Bristol-Myers Squibb Co
NYSE:BMY
Other Assets
$21.8B
CAGR 3-Years
2%
CAGR 5-Years
27%
CAGR 10-Years
12%
Johnson & Johnson
NYSE:JNJ
Other Assets
$44.8B
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
8%
Pfizer Inc
NYSE:PFE
Other Assets
$68.4B
CAGR 3-Years
11%
CAGR 5-Years
3%
CAGR 10-Years
5%
Merck & Co Inc
NYSE:MRK
Other Assets
$21.7B
CAGR 3-Years
5%
CAGR 5-Years
2%
CAGR 10-Years
5%
Zoetis Inc
NYSE:ZTS
Other Assets
$2.7B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Other Assets
$5.8B
CAGR 3-Years
14%
CAGR 5-Years
9%
CAGR 10-Years
N/A
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Market Cap
117.1B USD
Industry
Pharmaceuticals
Economic Moat
None

Bristol-Myers Squibb Co., with its storied history stretching back over 100 years, has cemented its place among the giants in the pharmaceutical industry. Rooted in a relentless quest for innovation, the company is a powerhouse in biopharmaceuticals, specializing in the development of groundbreaking medicines to address some of the world's most pressing medical challenges. From its vast portfolio, Bristol-Myers Squibb focuses on creating treatments that profoundly improve and extend lives, targeting conditions like cancer, cardiovascular diseases, and immune disorders. This sharp focus on specific therapeutic areas allows the company to leverage its research acumen and clinical expertise fully. It consistently nurtures innovation through robust investment in research and development, collaborating with universities, research institutes, and biotechnology firms to stay ahead in a fiercely competitive field. Making money in the pharmaceutical sector involves a delicate dance of science, strategic marketing, and regulatory navigation, and Bristol-Myers Squibb has mastered this choreography. The company generates revenue primarily through the sale of its prescription medications, which follow a comprehensive journey from initial R&D and clinical trials through rigorous regulatory approval processes and, ultimately, to market launch. Blockbuster drugs like Opdivo and Eliquis, which cater to oncology and cardiovascular therapy markets respectively, bring in substantial revenue, driven by their efficacy and the global demand for effective treatments. Moreover, the company's commitment to expanding its pipeline ensures a steady flow of new products and maintains its competitive edge. By continually evaluating its portfolio and capitalizing on emerging medical needs, Bristol-Myers Squibb not only sustains its financial health but also solidifies its reputation as a leader in transforming patients' futures.

BMY Intrinsic Value
70.82 USD
Undervaluation 18%
Intrinsic Value
Price

See Also

What is Bristol-Myers Squibb Co's Other Assets?
Other Assets
21.8B USD

Based on the financial report for Sep 30, 2024, Bristol-Myers Squibb Co's Other Assets amounts to 21.8B USD.

What is Bristol-Myers Squibb Co's Other Assets growth rate?
Other Assets CAGR 10Y
12%

Over the last year, the Other Assets growth was 3%. The average annual Other Assets growth rates for Bristol-Myers Squibb Co have been 2% over the past three years , 27% over the past five years , and 12% over the past ten years .

Back to Top